Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Charts for Quick CASH $$$ -- Ignore unavailable to you. Want to Upgrade?

To: Carlton G Glenn who wrote (4536)	10/23/1997 11:18:00 PM
From: Galirayo	Read Replies (1) \| Respond to of 9262

Say Waaaaaaaat?

To: Carlton G Glenn who wrote (4536)	10/24/1997 3:35:00 PM
From: Galirayo	Read Replies (1) \| Respond to of 9262

[ BJCT ] Carl, Here is an interesting one. It just broke it's last top today. Looks like a V Reversal. Ray Bioject Medical Technologies and Elan Corporation Form Joint Venture and Drug Delivery Alliance Anticipated First Product is a Patch-Like Sensor and Wrist Watch-Type Monitoring Device that Measures Glucose Levels on a 24-Hour Basis Elan Agrees To Make $3 Million Equity Investment in Bioject And To Invest $500,000 in Bioject's Development of Needle-Free Pre-Fill Technology PORTLAND, Ore., Oct. 1 /PRNewswire/ -- Bioject Medical Technologies (Nasdaq:BJCT) today announced it has established a joint venture with Elan Corporation, plc (NYSE:ELN) for the research, development, and commercialization of a continuous glucose level monitoring system for diabetics. The ambulatory monitoring system will comprise a patch-like sensor coupled with a wrist watch-type monitoring device that continuously and precisely measures glucose levels on a 24-hour basis. This real-time monitoring system, whose sensor will require changing only once daily, should serve as the preferred alternative for diabetics who now rely on static glucose monitoring systems requiring self-administered finger-prick readings at least four times daily. Human clinical trials for the monitoring system are expected to begin in early 1998. [snip] biz.yahoo.com